Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Thursday

Praxis Precision Medicines (NASDAQ:PRAX) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Praxis Precision Medicines to post earnings of ($3.00) per share and revenue of $0.2560 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Praxis Precision Medicines Stock Performance

Shares of Praxis Precision Medicines stock opened at $323.29 on Thursday. Praxis Precision Medicines has a twelve month low of $26.70 and a twelve month high of $328.60. The firm has a market cap of $8.15 billion, a P/E ratio of -25.06 and a beta of 2.84. The firm’s 50-day simple moving average is $290.07 and its 200-day simple moving average is $165.77.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PRAX shares. Guggenheim restated a “buy” rating and issued a $800.00 target price (up previously from $760.00) on shares of Praxis Precision Medicines in a research note on Tuesday. Wells Fargo & Company initiated coverage on Praxis Precision Medicines in a research report on Monday, February 2nd. They issued an “equal weight” rating and a $282.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Praxis Precision Medicines in a research note on Monday, December 29th. Wedbush raised their target price on Praxis Precision Medicines from $83.00 to $95.00 and gave the company an “underperform” rating in a research note on Monday, January 12th. Finally, TD Cowen reiterated a “buy” rating on shares of Praxis Precision Medicines in a research report on Thursday, January 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $536.06.

Insider Buying and Selling at Praxis Precision Medicines

In related news, insider Lauren Mastrocola sold 13,600 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $192.08, for a total transaction of $2,612,288.00. Following the completion of the sale, the insider directly owned 10,442 shares of the company’s stock, valued at $2,005,699.36. The trade was a 56.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Alex Nemiroff sold 25,130 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the completion of the sale, the general counsel owned 20,832 shares in the company, valued at approximately $4,022,450.88. This trade represents a 54.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 2.70% of the company’s stock.

Institutional Trading of Praxis Precision Medicines

Several hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its position in Praxis Precision Medicines by 24.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock valued at $77,000 after purchasing an additional 359 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Praxis Precision Medicines in the 4th quarter valued at about $163,000. Norges Bank acquired a new stake in shares of Praxis Precision Medicines in the second quarter valued at about $210,000. O Shaughnessy Asset Management LLC bought a new stake in Praxis Precision Medicines during the fourth quarter worth about $226,000. Finally, BNP Paribas Financial Markets boosted its position in Praxis Precision Medicines by 114.2% during the third quarter. BNP Paribas Financial Markets now owns 4,385 shares of the company’s stock valued at $232,000 after purchasing an additional 2,338 shares during the last quarter. Institutional investors and hedge funds own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.